Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 192

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 192
---
 management plans: |

The Company
is in the research and development (R&D) stage and, as such, has not generated any revenues from its current operations. The Company’s
activities are primarily funded through investment. As of December 31, 2024, the Company reported an accumulated deficit of $11,513.

To support
its operations and advance its development programs, the Company intends to continue securing investments. Management anticipates that
additional capital will be necessary to fund its ongoing R&D activities and to explore opportunities for acquiring healthcare or
healthcare-related technologies. However, there are currently no binding commitments for further investment, and there can be no assurance
that the Company will secure the required capital on commercially reasonable terms, or at all.

If sufficient
investment cannot be obtained, the Company may need to implement cost-cutting measures, scale back its R&D activities, or delay certain
development programs. Despite these potential challenges, management and the board of directors believe that the Company’s existing
financial resources will be sufficient to sustain its planned operations for at least the next twelve months.

The consolidated
financial statements do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts
and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

<div align='center'>F-8</div>

REVIUM RX.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands

NOTE 1 – GENERAL (Cont.)

To date, Predecessor
has not generated any revenue from its current operations and therefore is dependent upon external sources for financing its operations.
As of July 23, 2024, and December 31, 2023, the Predecessor had an accumulated deficit of $3,343 and $1,922, respectively Furthermore,
the Company intends to continue to finance the operating activities of the Predecessor by raising capital. As of December 31, 2023, the
Predecessor has raised approximately $3,109. The Successor has declared it will continue financing Predecessor’s activity. If the
Predecessor will not have sufficient liquidity resources, the Company may not be able to continue the development of its product candidates
or may be required to implement a cost reduction and/or delay part of its development programs.

| c. | Impact of the “Iron Swords” War on Israel: |

In October
2023, Hamas terrorists infiltrated Israel’s southern border from the